MedPath

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

Phase 3
Completed
Conditions
Cervix, Dysplasia
HIV Infections
Registration Number
NCT00001073
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to see if it is safe and effective to give isotretinoin to HIV-infected women with cervical tumors to prevent these tumors from becoming cancerous.

Cervical tumors are found in both HIV-infected and HIV-negative women. However, HIV-infected women are at a greater risk, and often their tumors become cancerous more quickly than those in HIV-negative women. Isotretinoin may be able to prevent this from happening. However, since these tumors tend to disappear over time, many doctors are hesitant to give their patients isotretinoin since this drug causes birth defects. This study looks at whether it is better to treat cervical tumors in HIV-infected women or to wait and see if they will disappear by themselves.

Detailed Description

Cervical neoplasia is frequently seen in HIV-infected women, apparently resulting from immunosuppression and common risk factors, including sexual behavior patterns. In HIV seronegative women, progression of preinvasive neoplasia is relatively slow, and up to 40 percent of low grade squamous intraepithelial lesions (grade I CIN/HPV-associated changes) regress to a normal appearance over time. Many clinicians have opted not to treat CIN I/HPV-associated changes due to this high spontaneous regression rate. Currently, retinoids, principally isotretinoin, are the most consistently effective medical therapy for CIN/HPV-associated changes, but use of isotretinoin in HIV-infected patients has not been extensively documented. (AS PER AMENDMENT 6/10/97)

Patients are randomized to receive oral isotretinoin for 6 months or be observed only for 6 months, with 12 additional months of follow-up. \[AS PER AMENDMENT 7/23/99: Follow-up time has been decreased to 9 months from the last patient enrolled.\]

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (40)

Bmc Actg Crs

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

Hosp. of the Univ. of Pennsylvania CRS

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

UW School of Medicine - CHRMC

πŸ‡ΊπŸ‡Έ

Seattle, Washington, United States

Duke Univ. Med. Ctr. Adult CRS

πŸ‡ΊπŸ‡Έ

Durham, North Carolina, United States

NY Univ. HIV/AIDS CRS

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Indiana Univ. School of Medicine, Infectious Disease Research Clinic

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

Ucsd, Avrc Crs

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

SUNY - Buffalo, Erie County Medical Ctr.

πŸ‡ΊπŸ‡Έ

Buffalo, New York, United States

Alabama Therapeutics CRS

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

USC CRS

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

UCLA CARE Center CRS

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Usc La Nichd Crs

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Santa Clara Valley Med. Ctr.

πŸ‡ΊπŸ‡Έ

San Jose, California, United States

San Mateo County AIDS Program

πŸ‡ΊπŸ‡Έ

San Mateo, California, United States

Howard University Hosp., Div. of Infectious Diseases, ACTU

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

Univ. of Florida Jacksonville NICHD CRS

πŸ‡ΊπŸ‡Έ

Jacksonville, Florida, United States

Northwestern University CRS

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Rush Univ. Med. Ctr. ACTG CRS

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Johns Hopkins Adult AIDS CRS

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

St. Louis ConnectCare, Infectious Diseases Clinic

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Washington U CRS

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

NJ Med. School CRS

πŸ‡ΊπŸ‡Έ

Newark, New Jersey, United States

Beth Israel Med. Ctr. (Mt. Sinai)

πŸ‡ΊπŸ‡Έ

New York, New York, United States

SUNY Upstate Med. Univ., Dept. of Peds.

πŸ‡ΊπŸ‡Έ

Syracuse, New York, United States

Memorial Sloan-Kettering Cancer Ctr.

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Univ. of Rochester ACTG CRS

πŸ‡ΊπŸ‡Έ

Rochester, New York, United States

The Ohio State Univ. AIDS CRS

πŸ‡ΊπŸ‡Έ

Columbus, Ohio, United States

University of Washington AIDS CRS

πŸ‡ΊπŸ‡Έ

Seattle, Washington, United States

San Juan City Hosp. PR NICHD CRS

πŸ‡΅πŸ‡·

San Juan, Puerto Rico

Puerto Rico-AIDS CRS

πŸ‡΅πŸ‡·

San Juan, Puerto Rico

Mbeya Med. Research Program, Mbeya Referral Hosp. CRS

πŸ‡ΉπŸ‡Ώ

Mbeya, Tanzania

Ucsf Aids Crs

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

South Florida CDC Ft Lauderdale NICHD CRS

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

Univ. of Miami AIDS CRS

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Univ. of Hawaii at Manoa, Leahi Hosp.

πŸ‡ΊπŸ‡Έ

Honolulu, Hawaii, United States

Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Tulane/LSU Maternal/Child CRS

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Unc Aids Crs

πŸ‡ΊπŸ‡Έ

Chapel Hill, North Carolina, United States

Β© Copyright 2025. All Rights Reserved by MedPath